Haleon – new name for the makers of Sensodyne announced by GSK
GlaxoSmithKline (GSK) today announced that a new company, resulting from the proposed demerger of its consumer healthcare business later this year, will be called Haleon.
A statement explained: “Haleon is inspired by the merging of ‘hale’, an old English word meaning ‘in good health’ and leon, which is associated with the word ‘strength’.” Haleon will have a portfolio of global brands, including Sensodyne, Voltaren, Panadol and Centrum.
The company said that the new brand identity was developed with input from employees, healthcare practitioners and consumers and will be deployed in more than 100 markets around the world where the business operates.
The creation of Haleon results from a series of investments and strategic changes to GSK’s consumer health business over the last eight years, including integrations of the consumer product portfolios from Novartis and Pfizer. It is now a global business generating annual sales of approximately £10 billion.
As a standalone company, GSK said Haleon will be a “new world-leader in consumer healthcare, offering a compelling proposition – to bring deep human understanding together with trusted science – to deliver better everyday health with humanity.”
Brian McNamara, chief executive officer designate of Haleon, said: “Introducing Haleon to the world marks another step in our journey to become a new, standalone company. Our name is grounded in our purpose to deliver better everyday health with humanity and to be a world-leader in consumer healthcare.
“We are on track to launch Haleon in mid-2022 and our business momentum is strong. We look forward to updating investors and analysts more on this at our capital markets event at the end of February.”
Emma Walmsley, chief executive officer of GSK, added: “Haleon brings to life years of hard work by many outstanding people to build this new company purely dedicated to everyday health. Haleon has enormous potential to improve health and wellbeing across the world with strong prospects for growth, and through listing will unlock significant value for GSK shareholders.”
The name was announced in advance of GSK hosting a Consumer Healthcare Capital Markets Day for investors and analysts on 28 February, to provide details on the overall strategy, capabilities and operations of Haleon, including detailed financial information and growth ambitions of the business.